These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 30539507)

  • 1. Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice.
    Masarova L; Kantarjian H; Ravandi F; Sharma P; Garcia-Manero G; Daver N
    Adv Exp Med Biol; 2018; 995():97-116. PubMed ID: 30539507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
    Masarova L; Kantarjian H; Garcia-Mannero G; Ravandi F; Sharma P; Daver N
    Adv Exp Med Biol; 2017; 995():73-95. PubMed ID: 28321813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
    Liu Y; Bewersdorf JP; Stahl M; Zeidan AM
    Blood Rev; 2019 Mar; 34():67-83. PubMed ID: 30553527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emerging role of immune checkpoint based approaches in AML and MDS.
    Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
    Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors.
    Assi R; Kantarjian H; Ravandi F; Daver N
    Curr Opin Hematol; 2018 Mar; 25(2):136-145. PubMed ID: 29206680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for myelodysplastic syndrome and acute myeloid leukemia: where do we stand?
    Spillane DR; Assouline S
    Expert Rev Hematol; 2023; 16(11):819-834. PubMed ID: 37819154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging Immunotherapy for Acute Myeloid Leukemia.
    Tabata R; Chi S; Yuda J; Minami Y
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelodysplastic syndrome and immunotherapy novel to next in-line treatments.
    Linder K; Lulla P
    Hum Vaccin Immunother; 2021 Aug; 17(8):2602-2616. PubMed ID: 33941042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reinforcing the primary immunotherapy modulators against acute leukemia; monoclonal antibodies in AML.
    Mahalleh M; Shabani M; Rayzan E; Rezaei N
    Immunotherapy; 2019 Dec; 11(18):1583-1600. PubMed ID: 31841068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1 signaling and inhibition in AML and MDS.
    Haroun F; Solola SA; Nassereddine S; Tabbara I
    Ann Hematol; 2017 Sep; 96(9):1441-1448. PubMed ID: 28643044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Blockade in Breast Cancer Therapy.
    Bu X; Yao Y; Li X
    Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BITES and CARS and checkpoints, oh my! Updates regarding immunotherapy for myeloid malignancies from the 2018 annual ASH meeting.
    Przespolewski AC; Griffiths EA
    Blood Rev; 2020 Sep; 43():100654. PubMed ID: 32029263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in Acute Myeloid Leukemia: Where We Stand.
    Isidori A; Cerchione C; Daver N; DiNardo C; Garcia-Manero G; Konopleva M; Jabbour E; Ravandi F; Kadia T; Burguera AF; Romano A; Loscocco F; Visani G; Martinelli G; Kantarjian H; Curti A
    Front Oncol; 2021; 11():656218. PubMed ID: 34041025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
    Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
    Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors.
    Tettamanti S; Magnani CF; Biondi A; Biagi E
    Immunol Lett; 2013; 155(1-2):43-6. PubMed ID: 24076117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors.
    Gay F; D'Agostino M; Giaccone L; Genuardi M; Festuccia M; Boccadoro M; Bruno B
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):471-478. PubMed ID: 28689001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid Leukemia.
    Haddad F; Zeidan AM; Daver N
    Cancer J; 2022 Jan-Feb 01; 28(1):43-50. PubMed ID: 35072373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Gallazzi M; Ucciero MAM; Faraci DG; Mahmoud AM; Al Essa W; Gaidano G; Mouhssine S; Crisà E
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.